TML‐6, A Novel Oral Multi‐Target Drug: Design of a Global Phase II Trial Investigating Safety, Tolerability, and Efficacy with Integration of Blood Biomarkers in Early Alzheimer’s Disease.
TML-6; blood biomarkers; Alzheimer's disease; autophagy regulation; β-amyloid clearance; anti-inflammation Correspondence to: Ih-Jen Su E-mail: [email protected].
Authors
- C Lin (ORCID: https://orcid.org/0000-0002-7510-6542)
- Shang Hung Chen
- Ih‐Jen Su
- Hui‐Chen Wang
- Chia‐Yu Hsu
Institutions
- National Health Research Institutes (TW)
- Southern Taiwan University of Science and Technology (TW)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_096730
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00